Clinical trial
Dose Ranging Study to Evaluate the Safety and Efficacy of Mapracorat Ophthalmic Formulation, in Subjects With Allergic Conjunctivitis Compared to Vehicle in a Conjunctival Allergen Challenge (CAC).
NCT01289431 is registered in ClinicalTrials.gov with Bausch & Lomb Incorporated as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Dose Ranging Study to Evaluate the Safety and Efficacy of Mapracorat Ophthalmic Formulation, in Subjects With Allergic Conjunctivitis Compared to Vehicle in a Conjunctival Allergen Challenge (CAC).
- Lead sponsor
- Bausch & Lomb Incorporated
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- February 28, 2011
- Completion date
- April 30, 2011
- Enrollment
- 236 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.